Open AccessRationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
Author(s) -
D. Clark Files,
Frank Tacke,
Alexandra O’Sullivan,
Patrick Dorr,
William Ferguson,
William G. Powderly
Publication year - 2022
Publication title -
plos pathogens
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.719
H-Index - 206
eISSN - 1553-7374
pISSN - 1553-7366
DOI - 10.1371/journal.ppat.1010547
Subject(s) - medicine , ccr2 , clinical trial , ccr5 receptor antagonist , chemokine receptor , immunology , chemokine , inflammation
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom